7 recruiting, 5 not yet recruiting, 1 active not recruiting, 1 completed. 8 Phase 2, 4 Phase 1, 2 Early Phase 1, 2 Not applicable, 1 Phase 4.
Follow cGVHD: new trials by email Literature Review of cGVHD trials Research Report on cGVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease Axatilimab - Chronic Graft vs. Host Disease, GVHD | Not yet recruiting | Northwestern University | 15 | 2026-11-01 | 2026-09-22 | |
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil, Ruxolitinib - cGVHD | Phase 2 | Not yet recruiting | Dennis Kim | 53 | 2026-11-01 | 2026-10-02 |
| Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib - Hematopoietic Stem Cell Transplantation (HSCT), cGVHD | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 170 | 2026-10-01 | 2026-08-31 |
| IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD Belumosudil, Sarilumab - cGVHD | Phase 1 | Not yet recruiting | Stanford University | 10 | 2026-09-01 | 2026-08-12 |
| Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD anti-CD25 rhMAb, Prednisone, Ruxolitinib - cGVHD | Phase 4 | Not yet recruiting | Peking University People's Hospital | 30 | 2026-07-15 | 2026-06-18 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). Gecacitinib - cGVHD, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2026-03-16 | 2026-03-17 |
| A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD) GT729 Injection - cGVHD | Early Phase 1 | Recruiting | Grit Biotechnology | 36 | 2025-12-18 | 2026-04-14 |
| BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation BPC-2001 - Graft -Versus-host-disease, aGVHD | Phase 2 | Recruiting | BioPhoenix Co., Ltd. | 50 | 2025-10-29 | 2026-08-17 |
| Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 Donor-derived Treg cell injection combined with interleukin 2 - cGVHD | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 18 | 2025-06-14 | 2025-09-30 |
| Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease Axatilimab, Extracorporeal Photopheresis - Chronic Graft Versus Host Disease, cGVHD | Phase 2 | Recruiting | University of Miami | 49 | 2025-05-05 | 2026-06-22 |
| Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease Tele-palliative care visit - Chronic Graft-versus-host Disease, Chronic GVHD | Not applicable | Active not recruiting | Massachusetts General Hospital | 10 | 2024-09-09 | 2026-04-06 |
| Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD Iguratimod - cGVHD | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | 20 | 2024-01-10 | 2026-09-30 |
| Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease Non-Interventional - cGVHD | Recruiting | Incyte Corporation | 1500 | 2023-08-01 | 2026-10-06 | |
| A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) ABSK021 - cGvHD | Phase 2 | Enrolling by invitation | Abbisko Therapeutics Co, Ltd | 64 | 2023-05-30 | 2024-08-12 |
| Belimumab for Treatment of cGVHD Following Allo-HCT Belimumab (Benlysta) - cGVHD | Phase 1 / Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 | |
| Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Rabbit ATG - aGVHD, cGVHD | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2019-02-01 | 2022-02-22 |
| Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease Graft vs Host Disease, Chronic Graft vs Host Disease | Completed | Dana-Farber Cancer Institute | 12 | 2010-09-01 | 2015-03-31 |
Bronchiolitis Obliterans Syndrome (4) · Graft vs Host Disease (2)
Immune System Diseases (6) · Bronchial Diseases (4) · Bronchiolitis (4) · Bronchiolitis Obliterans (4) · Bronchitis (4) · Graft vs Host Disease (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Organizing Pneumonia (4) · Respiratory Tract Diseases (4)
axatilimab (2) · belumosudil (2) · ruxolitinib (2) · Antilymphocyte Serum (1) · Cyclosporine (1) · Interleukin-2 (1) · KRN 7000 (1) · Photopheresis (1) · Prednisone (1) · belimumab (1) · iguratimod (1) · sarilumab (1) · thymoglobulin (1)
Abbisko Therapeutics Co, Ltd (1) · BioPhoenix Co., Ltd. (1) · Chinese PLA General Hospital (1) · Dana-Farber Cancer Institute (1) · Dennis Kim (1) · First Affiliated Hospital of Zhejiang University (1) · Grit Biotechnology (1) · Incyte Corporation (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Massachusetts General Hospital (1) · Northwestern University (1) · Peking University People's Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Stanford University (1) · University of Miami (1)
China (8) · United States (5) · Canada (1)
Alexander Misharin, MD, PhD (1) · Daihong Liu, Doctor (1) · Jennifer Huang, MD (1) · Kehinde Adekola, MD (1) · Sally Arai, MD (1) · Trent P Wang, DO (1) · Xiaodong Mo, PhD (1)